Niagen Bioscience, Inc 8-K, filed Dec 9, 2020
Niagen Bioscience, Inc. (NAGE)
8-K
2020-12-09
For: 2020-12-09
View Original
Added on
April 10, 2026
About this 8-K
Niagen Bioscience, Inc filed this 8-K on December 9, 2020.
Items reported
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________
FORM 8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR
15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): December 9,
2020
(Exact name of registrant as specified in its
charter)
|
|
|
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
(Address
of principal executive offices, including zip code)
(310 )
388-6706
(Registrant's telephone number, including area
code)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class
|
Trading
Symbol(s)
|
Name of
each exchange on which registered
|
|
|
|
The
|
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the
Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging growth
company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01.
Regulation FD Disclosure.
On
December 9, 2020, ChromaDex Corporation (the “Company”)
released a corporate presentation which it made available on its
website and which it will utilize in its presentation at the
December 2020 Benzinga Small Cap Conference on December 9, 2020,
held virtually. A copy of the corporate presentation is attached
hereto as Exhibit 99.1.
The
information in this report (including Exhibit 99.1 hereto) is being
“furnished” and shall not be deemed “filed”
for the purposes of Section 18 of the Securities Exchange Act of
1934, as amended, is not subject to the liabilities of that section
and is not deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Securities Exchange Act
of 1934, as amended, except as shall be expressly set forth by
specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number
|
Description
|
|
| 99.1 |
|
Investor
Presentation of ChromaDex Corporation
|
|
104
|
|
Cover
Page Interactive Data File (embedded within the Inline XBRL
document)
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
CHROMADEX CORPORATION
|
||
|
|
|
|
||||
|
Dated:
December 9, 2020
|
|
|
|
|
||
|
|
|
|
|
|||
|
|
|
|
|
By:
|
|
/s/
Kevin M. Farr
|
|
|
|
|
|
|
|
Name:
Kevin M. Farr
|
|
|
|
|
|
|
|
Chief
Financial Officer
|
Exhibit 99.1
